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Background: Data derived from the Cardiovascular Outcomes in Renal Atherosclerotic Lesions
(CORAL) study were analyzed in an effort to employ machine learning methods to predict the
composite endpoint described in the original study.
Methods: We identified 573 CORAL subjects with complete baseline data and the presence or
absence of a composite endpoint for the study. These data were subjected to several models including
a generalized linear (logistic-linear) model, support vector machine, decision tree, feed-forward
neural network, and random forest, in an effort to attempt to predict the composite endpoint. The
subjects were arbitrarily divided into training and testing subsets according to an 80%:20% distribution with various seeds. Prediction models were optimized within the CARET package of R.
Results: The best performance of the different machine learning techniques was that of the
random forest method which yielded a receiver operator curve (ROC) area of 68.1%±4.2%
(mean ± SD) on the testing subset with ten different seed values used to separate training and
testing subsets. The four most important variables in the random forest method were SBP, serum
creatinine, glycosylated hemoglobin, and DBP. Each of these variables was also important in
at least some of the other methods. The treatment assignment group was not consistently an
important determinant in any of the models.
Conclusion: Prediction of a composite cardiovascular outcome was difficult in the CORAL
population, even when employing machine learning methods. Assignment to either the stenting
or best medical therapy group did not serve as an important predictor of composite outcome.
Clinical Trial Registration: ClinicalTrials.gov, NCT00081731
Keywords: chronic kidney disease, cardiovascular disease, glomerular filtration rate, hypertension, ischemic renal disease, renal artery stenosis

Introduction
We have known for some time that atherosclerotic renal artery stenosis (ARAS) increases
the risk of kidney function decline leading to chronic kidney disease (CKD), cardiovascular disease, and death.1–3 However, the effect of renal artery revascularization by
stenting on renal and cardiovascular outcomes is inconsistent. Specifically, two large
randomized controlled trials, namely the ASTRAL and Cardiovascular Outcomes in
Renal Atherosclerotic Lesions (CORAL) studies, have demonstrated virtually identical
outcomes in patients treated with medical therapy alone or medical therapy plus stenting.4,5
That said, it is very clear that patients may have very different responses to renal artery
stenting, leading many clinicians to believe that prediction of responses to renal artery
stenting may be possible. One of the challenges for the completion of the CORAL study
49
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was the difficulty of convincing physicians at participating
centers that there was, in fact, equipoise regarding the utility
of stenting across the varied clinical presentations of ARAS.
While convincing the physicians of equipoise was difficult,
careful analysis of the CORAL data set to date has not yielded
clinical scenarios where medical therapy plus stenting was
either markedly better or worse than medical therapy alone.
On this background, there are a number of machine
learning methods which can be applied to clinical data sets.
A few studies have recently reported on the utility of these
methods for predicting renal outcomes in the classic MDRD
study.6 To the best of our knowledge, neither CORAL nor
ASTRAL data sets have been analyzed with machine learning approaches. With the idea that these machine learning
methods might discern patterns which are opaque to routine
clinical judgment, the following reanalysis of the CORAL
data set was undertaken.

Methods
CORAL trial
CORAL is a prospective, international, multicenter clinical
trial that randomly assigned 931 participants with ARAS who
received optimal medical therapy to stenting vs no stenting.
Enrollment began on May 16, 2005 and concluded on January
30, 2012 with follow-up until September 28, 2012, at which
time study objectives were accomplished and statistical power
was sufficient for the primary trial outcome analyses. The
study protocol adhered to the principles of the Declaration of
Helsinki and was approved by the institutional review boards
(IRBs) or the ethics committees at each participating site. A
list of these IRBs can be found in the IRB supplement. All
participating subjects provided written informed consent.
Participants with ARAS were randomized in a 1:1 ratio to
medical therapy plus stenting or medical therapy alone. Neither participants nor the investigators or the study coordinators were blinded to group assignment. Both groups received
anti hypertensive therapy with a stepwise approach to achieve
the blood pressure target, starting with an angiotensin receptor blocker or an angiotensin-converting-enzyme inhibitor.
The primary endpoint for CORAL, as well as for the
current study, was the first occurrence of a major cardiovascular or renal event – this was a composite of death from
cardiovascular or renal causes, stroke, myocardial infarction,
hospitalization for congestive heart failure, progressive renal
insufficiency or need for renal replacement therapy. Detailed
study entry criteria and main outcomes of this trial have been
published.5 Patients with renal artery stenosis of at least 60%
were eligible if they had hypertension while receiving two or
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more antihypertensive agents or had an estimated glomerular
filtration rate (eGFR) <60 mL/min/1.73 m2. Angiograms were
analyzed for verification of stenosis by the Angiography Core
Lab for the study at the University of Virginia.

Statistical analyses
All analysis was performed using the open source program
R.7 Although 931 patients were present in the initial data
set, many of these patients had missing values (especially
baseline laboratory values). The data were cleaned by excluding variables with large numbers of missing values (>40%
missing values). Variables with more moderate amounts of
missing values that had numeric data had the average value
placed into missing value categories (<20% missing values).
Missing non-numerical data (eg, race, gender, smoking)
caused us to drop the subjects from further analysis. Analysis
of 573 subjects with complete records was then performed.
The R code was employed to clean these data as shown in
Supplementary material 1. Parameters used for subsequent
analysis are shown in Box 1. Before analyzing the data set
without missing values, multiple methods of imputation for
both missing categorical and continuous data were employed
and yielded results were similar to the results of analysis of
the cleansed data (data not shown).

Logistic regression and support vector
machine
We used a generalized linear (logistic regression) model our
default8 using only baseline variables for the prediction of
composite endpoint outcomes. In addition, we examined the
utility of a support vector machine (SVM) which involves
the multidimensional sorting of data based on the development of a hyperplane which best segregates the two classes.8
Using the CARET package,9 we employed two tuning
parameters to control the performance of the SVM: kernel
and C. Kernel is a complex function, which takes input from
a lower dimension and transforms it to a higher dimension,
and is useful in a nonlinear separation problem. We used the
radial kernel option from the CARET package. When radial
kernel is applied, one additional parameter, Sigma, needs
to be specified, since higher values of Sigma tend to cause
an over-fitting problem. The second tuning parameter used
was C, which is a regularization parameter and specifies the
penalty for misclassification. Larger values of C indicate a
larger misclassification penalty, and thus, the optimization
will choose a hyperplane that separates cases with as small
a margin of misclassification as possible. Alternatively, a
smaller value of C would yield a larger-margin separating
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Box 1 Data used for predictive models.
“Age.at.Enrollment” – age of subject
“Angina Yes/No” – presence of angina by history
“AntiPlatelet.Any.Baseline Yes/No” – use of antiplatelet agents at
baseline
“Baseline.Systolic.BP” – systolic BP at baseline
“Baseline.Diastolic.BP – diastolic BP at baseline
“BMI” – body mass index
“CKD_EPI.Cystatin.C.GFR.Baseline” – estimation of glomerular
filtration
Rate with formula including serum creatinine and cystatin C conc.
“CHF Yes/No” – heart failure by history
“CHOL” – plasma cholesterol
“Creatinine.Baseline”- serum creatinine concentration at baseline
“Cystatin.C.Baseline” – serum cystatin C concentration at baseline
“Diabetes.Mellitus.HCRI Yes/No” – presence of diabetes based on
HCRI criteria
“GenderMale” – male gender
“HBA1C” – percent of glycosylated hemoglobin
“Height..ins.” – height in ft./in.
“Hb” – blood hemoglobin concentration
“HDL” – high-density lipoprotein

“HTN.Total.Meds.Baseline” – number of antihypertensive meds at
baseline
“Hyperlipidemia Yes/No” – presence of hyperlipidemia at baseline
“LDLC” – low-density lipoprotein cholesterol
“MI Yes/No” – history of MI by history
“Potassium.Baseline” – serum potassium concentration at baseline
“Premature.Art.Dz Yes/No” – whether patient had accelerated
vascular disease
“Protein” – urinary protein concentration at baseline
“PVD Yes/No” – presence of peripheral vascular disease
Race – Ethnicity
“RaceAsian”
“RaceBlack or African American” “RaceNative Pacific Islander”
“RaceWhite” “Hispanic-.-Latino”
“Smoking Yes/No” – presence of smoking at baseline
“TIA...Stroke Yes/No” – history of either a transient ischemic episode
or a cerebrovascular accident
“Total.Meds.Overall.Baseline” – total number of medications at
baseline
“Treatment_Assignment – medical or stenting assignment
“Weight..lbs.” – weight in lbs.

Abbreviations: MI, myocardial infarction; MI, myocardial infarction; CKD, chronic kidney disease; conc., concentration; HCRI, Harvard Clinical Research Institute.

hyperplane, even if it misclassifies more points compared
with smaller-margin hyperplane. The best combination of
C and Sigma values is determined using cross-validation.10
Sigma and C values were optimized within the CARET package, and values of 1e-3 and 32 were used thereafter.

Random forest
The third method we applied is the random forest, which
employs decision trees to construct a predictive model using
a set of binary rules applied to calculate a target value.11 It
can be used for both classification and regression. The decision tree approach utilized three or more nodes. Random
forest uses a tree-based resembling method for reducing bias
and combines (average) the results from many decision tree
models obtained by bootstrap samples. There are two tuning
parameters for the random forest: the number of trees (ntree)
we would like to average and the number of variables (mtry)
randomly sampled as candidates at each split in each tree.
We examined the performance of decision trees with the
RPART package and random forests with the randomForest
package.12,13 With the random forest technique, ntree was set
at 1,000 and mtry was optimized at 9.

Neural network
We also tried a feed-forward neural network.14 Neural
network passes information through multiple layers of
processors. Similarly, neural network takes input from the
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data forming the bottom layer, processes it through multiple
neurons from multiple hidden layers, and returns the result
forming the top layer. The outputs of nodes in one layer are
inputs to the next layer where the inputs to each node are
combined using a weighted linear combination. Three tuning
parameters are needed: one is the number of hidden layers,
the second one is the number of nodes in each hidden layer,
and the third one is the decay parameter. The decay parameter restricts the weighting from being too large. Different
feed-forward neural network architectures were explored
using the nnet and neuralnet packages.15 We found optimal
performance with one hidden layer containing nine hidden
neurons with a decay value of 0.24 after initial exploration.

Model comparisons
The CARET package was used for comparison of the mature
models employing ten folds and three repeats.9,16 Other packages within R were used for different specific tasks (eg, nnet
for construction of the neural network and random forest
[randomForest] for constructing random forests).7,11,15–24 All
numerical data were centered and scaled prior to analysis with
all of the above methods. The R code used for these analyses
is shown in Supplementary material 2.

Training and test sets
In the first phase, we varied the tuning parameters on a training subset with the CARET package. For all analyses, three
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repeats of the ten folds were used. For the SVM, the Sigma
and C values were varied from 0.1 to 1. Once these parameters
were optimized for the different methods, we used different
seed values to split the training and testing sets (80% training:20% testing). We then employed the strategy of three
repeats of the ten-folds with CARET on the different training
subsets achieved, varying the seed to initiate randomization to
divide the set into training and testing subsets. Areas under the
curve for the receiver operator curve (ROC) were improved
by ~5%–7% by the inclusion of these baseline laboratory
values (data not shown).
Statistical comparisons of ROC values determined with
ten different seed values for splitting training and testing sets
were performed on data obtained both with the training and
testing sets. The overall data sets were compared with oneway ANOVA and individual group means compared using
unpaired t-test with Holm–Sidak correction for multiple
comparisons.7

Results
The results of the training and testing subsets are shown in
Table 1. Although the methodologies were quite different, it
was clear that all the machine learning methods except the
simple decision tree yielded very similar ROC areas and

Table 1 ROC values achieved with training and testing sets
Method

ROC (training), %

GLM
62.8±1.3
SVM
63.1±1.3
RPART
52.4±1.5
nnet
59.8±1.7
RF
67.7±1.9
Statistical comparison of training ROC
GLM
nnet
nnet
<0.01
RF
<0.01
<0.01
RPART
<0.01
<0.01
SVM
NS
<0.01
Statistical comparison of testing ROC
GLM
nnet
nnet
NS
RF
<0.01
<0.05
RPART
<0.01
<0.01
SVM
NS
NS

ROC (testing), %
62.7±3.7
65.3±4.1
53.0±1.2
63.1±3.2
68.1±4.3
RF

RPART

Discussion
<0.01
<0.01

<0.01

RF

RPART

<0.01
NS

<0.01

Notes: Results expressed as mean ± SD of n=10 trials with different seed values
used to split CORAL data set into training and testing subsets. Statistical comparison
of both training and testing ROC by ANOVA showed it to be highly significant.
Comparison of group means using Holm–Sidak correction for multiple comparisons
shown with significance reported as NS, P<0.05, and P<0.01 levels.
Abbreviations: CORAL, Cardiovascular Outcomes in Renal Atherosclerotic
Lesions; GLM, generalized linear method; NS, nonsignificant; ROC, receiver operator
curve; nnet, neural network; RF, random forest; RPART partition; SVM, support vector
machine.
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accuracy values. A comparison of the ROC curves from one
analysis which illustrates this is shown in Figure 1.
Representative confusion matrices are shown in Table 2.
Clearly, the SVM method was very much slanted toward
negative values. Balancing the training set with outcomes
avoided that solution which approached the trivial, but did
not improve overall accuracy (data not shown). The other
methods yielded more balanced results with training set
chosen randomly. The balance between sensitivity and
specificity was probably the best with the neural network
model (Table 2), although the random forest method
yielded the highest accuracy in most of the simulations
(Table 1).
Examining the factors emphasized by the machine learning methods, it is worthwhile to note that, while different measurements were emphasized by the different techniques, the
treatment assignment was not considered a strong predictor
by any model (Table 3). This supports the overall conclusion
of the CORAL study that stenting did not add materially to
medical therapy in the avoidance of composite cardiovascular
outcomes in ARAS. In contrast, the baseline SBP as well
as estimates of renal function appeared to be consistently
featured by the different models as top predictors of adverse
outcomes. This is also consistent with the CORAL findings
that, although the treatment groups were similar at baseline
with regard to SBP and measures of renal function, higher
SBP and lower eGFR were prevalent in subjects who experienced a composite endpoint event. While there may be some
correlation among estimates of renal function, creatinine was
consistently chosen as a top predictor of adverse outcomes by
the models, while eGFR, based on the CKD-epidemiology
collaboration cystatin C equation, was selected by only one
model as the fourth in importance.

We attempted to apply machine learning methods to develop
a strategy for predicting outcomes in atherosclerotic renal
artery disease. The CORAL data set was used as the substrate
for these methods.
Although we found that some classification methods outperformed others, the results were somewhat disappointing
with ROC values generally <0.7. We would emphasize that
these results were somewhat inferior to what we saw when
a similar suite of machine learning methods were applied
to the modification of diet in renal disease (MDRD) data
set. Although the MDRD data set was somewhat larger, we
expect that the clinical course of the subjects studied in the
MDRD (patients with advanced CKD) was somewhat easier
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1.0

0.8

Sensitivity

0.6

0.4

0.2

0.0
1.0

0.8

0.6

Specificity

0.4

0.2

0.0

Figure 1 Representative ROCs generated with different models with a seed of 2. Red is generalized linear, green the support vector machine, blue the decision tree, orange
the neural network, and purple the random forest model.
Abbreviation: ROC, receiver operator curve.

Table 2 Confusion matrices in different models
Method

True neg (n)

False pos (n)

False neg (n)

True pos (n)

Sens (%)

Spec (%)

Acc (%)

GLM
SVM
RPART
nnet
RF

68
81
72
60
80

29
39
35
24
30

15
2
11
23
3

14
4
8
19
13

33
9
19
44
30

82
98
87
72
96

65
67
63
63
74

Notes: Results selected from analysis performed with seed 2 chosen to generate training and testing sets. Sens refers to sensitivity at detecting a composite outcome (true
pos/[true pos + false neg]). Spec refers to specificity at excluding a composite outcome (true neg/[true neg + false pos]), and Acc refers to the accuracy of the assignment.
Although results are only shown with seed 2, results were very similar with different seeds, varying only by a few percentage points.
Abbreviations: GLM, generalized linear method; neg, negative; pos, positive; nnet, neural network; RF, random forest; RPART partition; SVM, support vector machine.

Table 3 Top four important variables with different models
Method

1

2

3

4

GLM
SVM
RPART
nnet
RF

SBP
SBP
SBP
LDL
SBP

Chol
Creat
Protein
TIA
Creat

Htn Meds
Cyst C
HbA1c
DBP
HbA1c

Potassium
eGFR
Diabetes
Creat
DBP

Notes: Data derived from seed =2. Similar results with different seeds for all models.
Abbreviations: Chol, cholesterol; Creat, creatinine; eGFR, estimated glomerular
filtration rate; GLM, generalized linear method; HbA1c, glycated hemoglobin; Htn,
hypertension; LDL, low-density lipoprotein; nnet, neural network; RF, random forest;
RPART partition; SVM, support vector machine; TIA, transient ischemic attack.
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to predict than that of the CORAL patients.5,6 This showed,
the random forest approach generally outperformed the
other methods, with the SVM having particular problems in
identifying patients who achieved composite endpoints when
trained with the unbalanced training set. The decision tree
also performed quite poorly, and we would emphasize that
this machine learning method most closely mirrors human
decision making with a limited number of measurements used
for categorization. This latter point along with the absence
of the treatment assignment on the top predictor lists sadly
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supports the contention that the prediction of outcomes in
patients with atherosclerotic renal artery disease based on
baseline clinical parameters is not trivial, and that stenting
does not materially affect outcomes in either the overall population or any clearly defined subset based on these baseline
clinical parameters.
In the current analysis, urinary protein derived from the
baseline urinalysis was used in our machine learning methods
rather than urinary albumin creatinine ratio as reported by
Murphy et al,25 as there were fewer missing values. Urinary
protein was not a consistently important predictor in any of
the models (Table 3). On this note, SBP and creatinine were
commonly included as important factors in the models studied. However, treatment group assignment was not, underlining the ineffectiveness of stenting to improve outcomes in
this population.
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Supplementary materials
Supplementary material 1: Data
import and cleaning
setwd(“C:/Users/shapiroj/Dropbox/Current Stuff/work”)
library(dplyr)
dat <- read.csv(“temp_coral_v3c.
csv”,stringsAsFactors=FALSE,na.string=c(“”,NA,”
“,”U”,”Unk”))
dim(dat)
dat1 = dat[,!apply(is.na(dat), 2, all)] # automatically get
rid of empty cols at the end
dim(dat1)
# get rid of time to event days and make outcome yes or no
k1 = ncol(dat1)-1;k1
colnames(dat1)[k1] <- “output1”
temp = dat1[,k1]
dat1[temp==1,k1] <- “yes”
dat1[temp==0,k1] <- “no”
dat1[,k1] <- factor(dat1[,k1])
dat2 <- dat1[,-ncol(dat1)] # get rid of last Days.to.Prim.
Endpoint
keep <- (apply(dat2,2,function(x) sum(is.na(x))) < 400)
sum(keep)
dat_temp = dat2[,keep]
dat1=dat_temp
# merge the clinical and laboratory data
cc=colnames(dat1)[1]
# add in labs
x1=read.csv(“TG.csv”)
x2=read.csv(“CHOL.csv”)
x3=read.csv(“HBA1C.csv”)
x4=read.csv(“HDL.csv”)
x5=read.csv(“LDL.csv”)
x6=read.csv(“Hb.csv”)
# create final dataset
dat1=full_join(x1,dat1, by=cc, copy=T)
dat1=full_join(x2,dat1, by=cc, copy=T)
dat1=full_join(x3,dat1, by=cc, copy=T)
dat1=full_join(x4,dat1, by=cc, copy=T)
dat1=full_join(x5,dat1, by=cc, copy=T)
dat1=full_join(x6,dat1, by=cc, copy=T)
# clean up memory
rm(x1)
rm(x2)
rm(x3)
rm(x4)
rm(x5)
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rm(x6)
# average in missing numerical data to reduce missing
values
vv=c(2:8,12:14,16:21,26,28)
#
mm=NULL
for(j in 1:length(vv)){
mm[j]=mean(dat1[,vv[j]],na.rm=T)
}
for(i in 1:length(vv)){
dat1[,vv[i]][is.na(dat1[,vv[i]])]=mm[i]
}
#sum(!complete.cases(dat3))
z=dat1[complete.cases(dat1),]
z=z[,-1]
z=z[complete.cases(z),]

Supplementary material 2:
Some variations used, version to
determine variable importance as
well as area under the curve (AUC)
for receiver operator curve (ROC)
and confusion matrix generation
library(ROCR)
library(pROC)
library(rpart)
library(caret)
library(nnet)
library(C50)
library(ggplot2)
library(randomForest)
# Could be run as a loop, but to avoid crashing, I ran them
individually
# kk=NULL
# #run simulations and save data
# kk=c(2,14,25,33,57,61)
sink(“VIP_coral”,append=FALSE)
print(“VIP_coral”)
sink()
# seed value set for 61 below, could have been a loop
kk=61
set.seed(kk)
ind = sample(2, nrow(z), replace = TRUE, prob = c(0.8, 0.2))
trainset = z[ind == 1,]
testset = z[ind == 2,]
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control = trainControl(method = “repeatedcv”, seeds=c(539,
704, 483, 253, 63, 887, 105, 65, 62, 343, 633, 870, 457,
422, 53, 189, 605, 628, 950, 781, 981, 284, 498, 198, 822,
150, 55, 166, 99, 874, 431), number = 10, repeats = 3,
classProbs = TRUE, summaryFunction = twoClassSummary)
glm.model = train(output1 ~ ., data = trainset, method
= “glm”, metric = “ROC”, trControl = control,
preProc=c(“center”,”scale”))
t=varImp(glm.model)
sink(“VIP_coral”,append=TRUE)
print(“glm”)
print(t)
sink()
tunGrid_svm=expand.grid(sigma=1e-3, C=32)
svm.model = train(output1 ~ ., data = trainset, method =
“svmRadial”,metric = “ROC”, tuneGrid=tunGrid_svm,
trControl = control, preProc=c(“center”,”scale”))
t=varImp(svm.model)
sink(“VIP_coral”,append=TRUE)
print(“svm”)
print(t)
sink()
rpart.model = train(output1 ~ ., data = trainset, method
= “rpart”, metric = “ROC”, trControl = control,
preProc=c(“center”,”scale”))
t=varImp(rpart.model)
sink(“VIP_coral”,append=TRUE)
print(“rpart”)
print(t)
sink()
tunGrid=expand.grid(size=c(9),decay=c(0.24))
nnet.model = train(output1 ~ ., data=trainset, method =
“nnet”, metric=”ROC”, trace=FALSE, trControl=control,
tuneGrid=tunGrid, preProc=c(“center”,”scale”))
t=varImp(nnet.model)
sink(“VIP_coral”,append=TRUE)
print(“nnet”)
print(t)
sink()
tunegrid=expand.grid(.mtry=9)
rfor.model = train(output1 ~ ., data=trainset, method =
“rf ”, metric=”ROC”, trControl=control,tuneGrid=tunegrid,
preProc=c(“center”,”scale”))
t=varImp(rfor.model)
sink(“VIP_coral”,append=TRUE)
print(“rfor”)
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print(t)
sink()
# make ROC comparisons
glm.probs = predict(glm.model, testset[,! names(testset)
%in% c(“output1”)], type = “prob”)
svm.probs = predict(svm.model, testset[,! names(testset)
%in% c(“output1”)], type = “prob”)
rpart.probs = predict(rpart.model, testset[,! names(testset)
%in% c(“output1”)], type = “prob”)
nnet.probs=predict(nnet.model, testset[,! names(testset)
%in% c(“output1”)], type = “prob”)
rfor.probs=predict(rfor.model, testset[,! names(testset)
%in% c(“output1”)], type = “prob”)
windows()
glm.ROC = roc(response = testset[, c(“output1”)],
predictor = glm.probs $yes, levels = levels(testset[,
c(“output1”)]))
plot(glm.ROC,add=F, col =” red”)
svm.ROC = roc(response = testset[, c(“output1”)],
predictor = svm.probs $yes, levels = levels(testset[,
c(“output1”)]))
plot(svm.ROC, add = TRUE, col =”green”)
rpart.ROC = roc(response = testset[, c(“output1”)],
predictor = rpart.probs $yes, levels = levels(testset[,
c(“output1”)]))
plot(rpart.ROC, add = TRUE, col =”blue”)
nnet.ROC=roc(response = testset[, c(“output1”)], predictor
= nnet.probs $yes, levels = levels(testset[, c(“output1”)]))
plot(nnet.ROC, add = TRUE, col =”orange”)
rfor.ROC=roc(response = testset[, c(“output1”)], predictor
= rfor.probs $yes, levels = levels(testset[, c(“output1”)]))
plot(rfor.ROC, add = TRUE, col =”purple”)
#make confusion matrix
print(“glm”)
glm.pred=predict(glm.model,testset[,!names(testset)%in%
c(“output1”)])
t=table(glm.pred,testset[,c(“output1”)])
tt=confusionMatrix(glm.pred,testset[,c(“output1”)])
print(tt)
print(“svm”)
svm.pred=predict(svm.model,testset[,!names(testset)%in%
c(“output1”)])
t=table(svm.pred,testset[,c(“output1”)])
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tt=confusionMatrix(svm.pred,testset[,c(“output1”)])
print(tt)

tt=confusionMatrix(nnet.pred,testset[,c(“output1”)])
print(tt)

print(“rpart”)
rpart.pred=predict(rpart.model,testset[,!names(testset)
%in% c(“output1”)])
t= table(rpart.pred,testset[,c(“output1”)])
tt=confusionMatrix(rpart.pred,testset[,c(“output1”)])
print(tt)

print(“rfor”)
rfor.pred=predict(rfor.model,testset[,!names(testset)%in%
c(“output1”)])
t=table(rfor.pred,testset[,c(“output1”)])
tt=confusionMatrix(rfor.pred,testset[,c(“output1”)])
print(tt)

print(“nn”)
nnet.pred=predict(nnet.model,testset[,!names(testset)
%in% c(“output1”)])
t= table(nnet.pred,testset[,c(“output1”)])
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